Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "ProActive Sports Therapy" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about ProActive Sports Therapy for you to read. Along with our medical data and news we also list ProActive Sports Therapy Clinical Trials, which are updated daily. BioPortfolio also has a large database of ProActive Sports Therapy Companies for you to search.
Once a 'refugee,' a gene therapy pioneer finds a renewed calling as the field advances. https://buff.ly/2V2iEbh
Raising Male Breast Cancer Awareness Throughout the Season HUNTINGTON STATION, N.Y. (PRWEB) February 15, 2019 For the second consecutive year, United Breast Cancer Foundation's print Call to Action Public Service Announcement (PSA), "Drive Out Breast Cancer®", is featured during the entire 2019 NASCAR (National Association for Stock Car Auto Racing) season in both editions of t...
According to American Heart Association’s 2018 statistics, cardiovascular disease accounts for nearly 836,546 deaths in the U.S. That’s about one of every three deaths, and about 92.1 million American adults are living with some form of cardiovascular disease or the after-effects of stroke.
Once a "refugee," gene therapy pioneer Jim Wilson is finding a renewed calling as the field advances.
-Janssen's #esketamine drug recommended by #FDA panel for #depression - Feature: Solving the drug development problem - #FMD would not apply in case of no-deal #Brexit - Gilead's CAR-T therapy #Yescarta rejected for #NHS use in #Scotland http://bit.
-Janssen's #esketamine drug recommended by #FDA panel for #depression - Feature: Solving the drug development problem - #FMD would not apply in case of no-deal #Brexit - Gilead's CAR-T therapy
Cross Country Healthcare, Inc. (Nasdaq: CCRN) announced today that it is scheduled to present at two upcoming conferences: The Barclays Global Healthcare Conference on Wednesday, March 13, 2019 at 3:50 p.m. Eastern Time, at the Loews Miami Beach Hotel in Miami Beach, Florida. The Oppenheimer 29th Annual Healthcare Confe...
Company plans to submit clinical study protocol for CMS consideration LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today recognized that the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its National Coverage Determination (NCD) for the LivaNova Vagus Nerve Stimulation Therapy® (VNS Therapy) System for T...
The study was aimed at the efficacy and safety of cerliponase alfa (Brineura, BioMarin) for patients with CLN2.
Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell
A developer of gene therapies for rare monogenic CNS diseases—whose co-founders include pioneer researcher James M. Wilson, MD, PhD—has launched with $115.5 million in Series A financing. Passage Bio said it will use proceeds from the financing to develop a portfolio of five therapeutic candidates that incorporate adeno-associated virus (AAV) technologies developed by Wilson and […] The ...
A Phase III clinical trial has shown that metastatic prostate cancer improved through the use of a combination therapy, with enzalutamide... The post Phase III combination trial improves sur
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the f...
NEWARK, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for seladelpar for the treatment of early stage primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adult patients with an inadequate response to UDCA, …
WHIPPANY, N.J., Feb. 14, 2019 /PRNewswire/ — Results from the pivotal Phase III ARAMIS trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a statistically significant improvement in metastasis-free survival (MFS) with the investigational drug darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT (HR=0.41, 95% C...
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced data evaluating Opdivo(nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from an interim analysis of the Phase 2 CheckMate -650 trial showed that among 32 asymptomatic or minimally symptomatic pat...
– Preliminary data from FIERCE-21 Phase 2 trial highlighted in oral presentation supports advancement to pivotal study – – Single agent activity and long-term treatment duration demonstrated – Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the presentation of preliminary data from ...
The U.S. Centers for Medicare & Medicaid Services (CMS) on Friday proposed coverage of expensive CAR-T cell therapies at cancer centers that meet criteria including an approved registry of patient results or clinical study to monitor patients for at ...
Celebrating its 25 Year Anniversary, EMASS Offers Adults Over 50 the Opportunity to Engage in Balanced Competition, Be Part of a Team, and Form Lifelong Friendships Entering its 25th season, the EMASS Senior Softball League is launching its annual recruitment campaign for players age 50 and over. The 400-plus member league draws players from towns acro...
- Doctor-directed dry eye therapy builds broad acceptance with doctors and patients - Dr. Crystal Brimer, founder of the Dry Eye Institute and owner of Focus Eye Care, Wilmington, NC, is the purchaser of the 2,000th NuLids System sold. NuLids, an innovative doct
(MedPage Today) -- Smokers with T cell-driven pathogenesis may benefit from targeted therapy
Stock price effects of breakthrough therapy designation https://go.nature.com/2X7gcSH - a new analysis by @Frank_S_David and colleagues pic.twitter.com/xxTpt5yS0U
RBS dividend beats forecast despite long-term Brexit caution Financial TimesRBS warns of Brexit damage despite profits more than doubling The GuardianFTSE 100 holds firm after UK retail sales boost; Lloyds, RBS find gains Proactive Investors UKRBS profits more than double amid bumper dividend payout Daily MailRBS more than doubles profits after branch closures - hands £977m to Government ...
@Genentech did you know we have a triple Cytokine immune therapy in development? One includes IL-15. #CallMeLetsTalk Genentech to Develop Xencor IL-15 Cytokines in Immuno-Oncology Partnership https://www.genengnews.com/news/genentech-to-develop-xencor-il
@Genentech did you know we have a triple Cytokine immune therapy in development? One includes IL-15. #CallMeLetsTalk Genentech to Develop Xencor IL-15 Cytokines in Immuno-Oncology Partnership https://www.genengnews.com/news/genentech-to-develop-xencor-il-15-cytokines-in-immuno-oncology-partnership/ … via
GammaTile Therapy is an FDA-cleared, surgically targeted radiation therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors. The first patient was treated by The post University of Minnesota to offer new targeted therapy for recurrent brain tumors appeared first on Compelo Medical Devices.